| Pair Name | Silibinin, Regorafenib | ||
| Phytochemical Name | Silibinin (PubChem CID: 31553 ) | ||
| Anticancer drug Name | Regorafenib (PubChem CID: 11167602 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Drug Name | Regorafenib |
| Adverse Reactions | Mouth and tongue sores, dizziness, itchy skin rashes all over the body, increased blood pressure. This was inferred hot nature anticancer drug. |
| Recommendations | Cold: Silybum marianum |
| Reference | Malignant tumors in the era of immunotherapy based on traditional Chinese medicine's "cold and hot theory" Construction of integrated traditional Chinese and Western medicine treatment paradigm[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine,2023,32(12):1712-1716. DOI:10.3969/j.issn.1008-8849.2023.12.022. ref_link |
| Pair Name | Silibinin, Regorafenib | |||
| Disease Info | [ICD-11: 2B91.Z] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->ROS generation | |||
| Gene Regulation | Down-regulation | Expression | PIK3CA | hsa5290 |
| Down-regulation | Expression | AKT1 | hsa207 | |
| Down-regulation | Expression | MTOR | hsa2475 | |
| In Vitro Model | SW48 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_1724 |
| HCT 15 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0292 | |
| SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 | |
| Result | The present study suggests that silybin in combination with regorafenib is a promising strategy for treatment of metastatic colorectal patients. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget. 2017 Aug 7;8(40):68305-68316. doi: 10.18632/oncotarget.20054. | Click |
